Christina Sewell

Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCM

Gary Parizher, Alice A. Haouzi, Wael A. Jaber, ANJALI TIKU OWENS et autres

us (code pays fourni par la source)

Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction

Milind Y. Desai, ANJALI TIKU OWENS, Kathy Wolski, Jeffrey B. Geske et autres

us (code pays fourni par la source)

Abstract 17216: Limited Concordance of Core Lab Left Ventricular Ejection Fraction With Automated Assessments: A Sub-Study From VALOR-HCM

Gary Parizher, Wael A. Jaber, ANJALI TIKU OWENS, Kathy Wolski et autres

Introduction: The performance of automated left ventricular ejection fraction (LVEF) assessment in patients with altered cardiac chamber geometry, such as those with obstructive hypertrophic cardiomyopathy (HCM), is not well described. Aims: Accurate assessment of LVEF is required for dose titration and continuation …

us (code pays fourni par la source)

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

Milind Y. Desai, ANJALI TIKU OWENS, Kathy Wolski, Jeffrey B. Geske et autres

Importance: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the …

us (code pays fourni par la source)

Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks

Milind Y. Desai, ANJALI TIKU OWENS, Jeffrey B. Geske, Kathy Wolski et autres

BACKGROUND: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal …

us (code pays fourni par la source)

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai, ANJALI TIKU OWENS, Jeffrey B. Geske, Kathy Wolski et autres

BACKGROUND: Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but is associated with morbidity and mortality. OBJECTIVES: This study sought to determine whether the oral myosin …

us (code pays fourni par la source)

Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy

Milind Y. Desai, Kathy Wolski, ANJALI TIKU OWENS, Srihari S. Naidu et autres

us (code pays fourni par la source)

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Paul C Cremer, Antonio Abbate, Kristin M. Hudock, Carla Sue McWilliams et autres

us (code pays fourni par la source)